Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating

Corvus Pharmaceuticals (CRVS) reported on its Q2 2026 earnings call that soquelitinib, its oral ITK inhibitor, is being tested in five diseases. In a Phase 1 atopic dermatitis cohort, 75% on 200 mg twice daily reached EASI-75 at 8 weeks vs 20% placebo. Corvus said it has $215M cash and expects Phase 2 SEERA-1 results after early 2027. R&D rose to $16M and net loss to $18M.

Corvus Pharmaceuticals (CRVS) reported Q2 2026 cash and marketable securities of $215.2 million as of June 30, 2026, including $189.4 million from a January follow-on offering. Net loss was $18.0 million versus $8.0 million a year earlier. Management said cash runway funds operations into Q2 2028 and outlined Phase III PTCL and Phase II atopic dermatitis timelines for soquelitinib.

Corvus Pharmaceuticals (NASDAQ:CRVS) said an interim futility analysis for its PTCL Phase III trial is expected in Q1 2027, with an independent committee deciding whether to continue. Final Phase III PTCL data are still expected in late 2027. For atopic dermatitis, soquelitinib Phase I results showed EASI-75 of 75% vs 20% placebo; SIERRA-1 enrollment ends early 2027 with top-line data in Q3 2027.

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib’s pote

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.